{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:58:36Z","timestamp":1793667516779,"version":"4.5.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s13555-025-01344-y","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:52:24Z","timestamp":1740163944000},"page":"563-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Recommendations to Improve Outcomes in Acne and Acne Sequelae: A Focus on Trifarotene and Other Retinoids"],"prefix":"10.1007","volume":"15","author":[{"given":"Naiem","family":"Issa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Woolery-Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JP","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate Zibilich","family":"Holcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-1563","authenticated-orcid":false,"given":"Rajeev","family":"Chavda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"5","key":"1344_CR1","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-73.e33.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1344_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13386","volume":"29","author":"L Liu","year":"2023","unstructured":"Liu L, Xue Y, Chen Y, et al. Prevalence and risk factors of acne scars in patients with acne vulgaris. Skin Res Technol. 2023;29(6): e13386.","journal-title":"Skin Res Technol"},{"issue":"6","key":"1344_CR3","first-page":"566","volume":"16","author":"J Tan","year":"2017","unstructured":"Tan J, Bourdes V, Bissonnette R, et al. Prospective study of pathogenesis of atrophic acne scars and role of macular erythema. J Drugs Dermatol. 2017;16(6):566\u201372.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1344_CR4","first-page":"21","volume":"11","author":"N Skroza","year":"2018","unstructured":"Skroza N, Tolino E, Mambrin A, et al. Adult acne versus adolescent acne: a retrospective study of 1,167 patients. J Clin Aesthet Dermatol. 2018;11(1):21\u20135.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"5","key":"1344_CR5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jaad.2023.12.038","volume":"90","author":"JH Saurat","year":"2024","unstructured":"Saurat JH, Halioua B, Baissac C, et al. Epidemiology of acne and rosacea: a worldwide global study. J Am Acad Dermatol. 2024;90(5):1016\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1344_CR6","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jaad.2020.02.040","volume":"83","author":"DV Samuels","year":"2020","unstructured":"Samuels DV, Rosenthal R, Lin R, et al. Acne vulgaris and risk of depression and anxiety: a meta-analytic review. J Am Acad Dermatol. 2020;83(2):532\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"1344_CR7","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/bjd\/ljad251","volume":"189","author":"O Hughes","year":"2023","unstructured":"Hughes O, Bewley A. Is it really ever \u201cjust acne\u201d? Considering the psychodermatology of acne. Br J Dermatol. 2023;189(Suppl 1):i11\u20136.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1344_CR8","first-page":"97","volume":"16","author":"J Tan","year":"2017","unstructured":"Tan J, Kang S, Leyden J. Prevalence and risk factors of acne scarring among patients consulting dermatologists in the USA. J Drugs Dermatol. 2017;16(2):97\u2013102.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"1344_CR9","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/jdv.14325","volume":"31","author":"J Tan","year":"2017","unstructured":"Tan J, Thiboutot D, Gollnick H, et al. Development of an atrophic acne scar risk assessment tool. J Eur Acad Dermatol Venereol. 2017;31(9):1547\u201354.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1344_CR10","first-page":"20","volume":"3","author":"EC Davis","year":"2010","unstructured":"Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20\u201331.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"1344_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/bjd.19477","volume":"184","author":"AM Layton","year":"2021","unstructured":"Layton AM, Thiboutot D, Tan J. Reviewing the global burden of acne: how could we improve care to reduce the burden? Br J Dermatol. 2021;184(2):219\u201325.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1344_CR12","first-page":"46","volume":"6","author":"YS Bae-Harboe","year":"2013","unstructured":"Bae-Harboe YS, Graber EM. Easy as pie (postinflammatory erythema). J Clin Aesthet Dermatol. 2013;6(9):46\u20137.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1344_CR13","unstructured":"Galderma. Burden summary report: Scarring. 2020. Galderma data on file."},{"key":"1344_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/CCID.S158129","volume":"11","author":"AO Akinboro","year":"2018","unstructured":"Akinboro AO, Ezejiofor OI, Olanrewaju FO, et al. The impact of acne and facial post-inflammatory hyperpigmentation on quality of life and self-esteem of newly admitted Nigerian undergraduates. Clin Cosmet Investig Dermatol. 2018;11:245\u201352.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"1344_CR15","first-page":"CD011946","volume":"4","author":"R Abdel Hay","year":"2016","unstructured":"Abdel Hay R, Shalaby K, Zaher H, et al. Interventions for acne scars. Cochrane Database Syst Rev. 2016;4(4):CD011946.","journal-title":"Cochrane Database Syst Rev"},{"key":"1344_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/CCID.S397888","volume":"16","author":"A Vempati","year":"2023","unstructured":"Vempati A, Zhou C, Tam C, et al. Subcision for atrophic acne scarring: A comprehensive review of surgical instruments and combinatorial treatments. Clin Cosmet Investig Dermatol. 2023;16:125\u201334.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"12","key":"1344_CR17","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s13555-023-01042-7","volume":"13","author":"S Schleicher","year":"2023","unstructured":"Schleicher S, Moore A, Rafal E, et al. Trifarotene reduces risk for atrophic acne scars: results from a Phase 4 controlled study. Dermatol Ther (Heidelb). 2023;13(12):3085\u201396.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1344_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/ijd.17189","volume":"63","author":"A Alexis","year":"2024","unstructured":"Alexis A, Del Rosso JQ, Forman S, et al. Importance of treating acne sequelae in skin of color: 6-month Phase iv study of trifarotene with an appropriate skincare routine including uv protection in acne-induced post-inflammatory hyperpigmentation. Int J Dermatol. 2024;63:806\u201315.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1344_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s13555-017-0185-2","volume":"7","author":"J Leyden","year":"2017","unstructured":"Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293\u2013304.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"22","key":"1344_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells12222600","volume":"12","author":"BC Melnik","year":"2023","unstructured":"Melnik BC. Acne transcriptomics: Fundamentals of acne pathogenesis and isotretinoin treatment. Cells. 2023;12(22):1\u201334.","journal-title":"Cells"},{"issue":"1","key":"1344_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4161\/derm.3.1.13900","volume":"3","author":"E Makrantonaki","year":"2011","unstructured":"Makrantonaki E, Ganceviciene R, Zouboulis C. An update on the role of the sebaceous gland in the pathogenesis of acne. Dermatoendocrinol. 2011;3(1):41\u20139.","journal-title":"Dermatoendocrinol"},{"issue":"9","key":"1344_CR22","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/jid.2012.111","volume":"132","author":"MC Dispenza","year":"2012","unstructured":"Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated tlr-2-mediated innate immune responses in acne patients. J Invest Dermatol. 2012;132(9):2198\u2013205.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1344_CR23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/ada.2019.87443","volume":"36","author":"M Zasada","year":"2019","unstructured":"Zasada M, Budzisz E. Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments. Postepy Dermatol Alergol. 2019;36(4):392\u20137.","journal-title":"Postepy Dermatol Alergol"},{"issue":"6","key":"1344_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/ijd.17220","volume":"63","author":"D Torocsik","year":"2019","unstructured":"Torocsik D. Trifarotene-based holistic management of acne. Int J Dermatol. 2024;63(6):697\u20138.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1344_CR25","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.jaad.2016.06.057","volume":"75","author":"JS Barbieri","year":"2016","unstructured":"Barbieri JS, Hoffstad O, Margolis DJ. Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (gp): A retrospective cohort study. J Am Acad Dermatol. 2016;75(6):1142-50.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1344_CR26","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jaad.2016.01.011","volume":"74","author":"S Pena","year":"2016","unstructured":"Pena S, Hill D, Feldman SR. Use of topical retinoids by dermatologists and non-dermatologists in the management of acne vulgaris. J Am Acad Dermatol. 2016;74(6):1252\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1344_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.067","volume":"76","author":"S Burchett","year":"2017","unstructured":"Burchett S. Is treatment of acne as simple as encouraging primary care physicians to prescribe more retinoids? J Am Acad Dermatol. 2017;76(1): e37.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1344_CR28","doi-asserted-by":"publisher","first-page":"1006e1","DOI":"10.1016\/j.jaad.2023.12.017","volume":"90","author":"RV Reynolds","year":"2024","unstructured":"Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006e1-e30.","journal-title":"J Am Acad Dermatol"},{"key":"1344_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jdin.2021.06.006","volume":"5","author":"A Layton","year":"2021","unstructured":"Layton A, Alexis A, Baldwin H, et al. Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the personalising acne: Consensus of experts panel. JAAD Int. 2021;5:41\u20138.","journal-title":"JAAD Int"},{"issue":"5","key":"1344_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamadermatol.2024.0203","volume":"160","author":"RA Festok","year":"2024","unstructured":"Festok RA, Ahuja AS, Chen JY, et al. Barriers and facilitators affecting long-term antibiotic prescriptions for acne treatment. JAMA Dermatol. 2024;160(5):535\u201343.","journal-title":"JAMA Dermatol"},{"key":"1344_CR31","doi-asserted-by":"publisher","first-page":"7591","DOI":"10.2147\/IJGM.S333501","volume":"14","author":"B Qumseya","year":"2021","unstructured":"Qumseya B, Goddard A, Qumseya A, et al. Barriers to clinical practice guideline implementation among physicians: a physician survey. Int J Gen Med. 2021;14:7591\u20138.","journal-title":"Int J Gen Med"},{"issue":"4","key":"1344_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.240","volume":"3","author":"L Corcoran","year":"2023","unstructured":"Corcoran L, Muller I, Layton AM, et al. Systematic review of clinical practice guidelines for acne vulgaris published between January 2017 and July 2021. Skin Health Dis. 2023;3(4): e240.","journal-title":"Skin Health Dis"},{"issue":"2","key":"1344_CR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jaad.2023.02.053","volume":"89","author":"S Taylor","year":"2023","unstructured":"Taylor S, Elbuluk N, Grimes P, et al. Treatment recommendations for acne-associated hyperpigmentation: Results of the delphi consensus process and a literature review. J Am Acad Dermatol. 2023;89(2):316\u201323.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1344_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40257-021-00643-2","volume":"23","author":"VD Callender","year":"2022","unstructured":"Callender VD, Baldwin H, Cook-Bolden FE, et al. Effects of topical retinoids on acne and post-inflammatory hyperpigmentation in patients with skin of color: A clinical review and implications for practice. Am J Clin Dermatol. 2022;23(1):69\u201381.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1344_CR35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaad.2004.10.879","volume":"54","author":"D Thiboutot","year":"2006","unstructured":"Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, Phase 3 trial. J Am Acad Dermatol. 2006;54(2):242\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"6 Suppl","key":"1344_CR36","first-page":"4","volume":"67","author":"GF Webster","year":"2001","unstructured":"Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: A randomized trial. Cutis. 2001;67(6 Suppl):4\u20139.","journal-title":"Cutis"},{"issue":"6","key":"1344_CR37","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.jaad.2019.02.044","volume":"80","author":"J Tan","year":"2019","unstructured":"Tan J, Thiboutot D, Popp G, et al. Randomized Phase 3 evaluation of trifarotene 50 \u00b5g\/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1344_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/jdv.15794","volume":"34","author":"U Blume-Peytavi","year":"2020","unstructured":"Blume-Peytavi U, Fowler J, Kemeny L, et al. Long-term safety and efficacy of trifarotene 50 \u00b5g\/g cream, a first-in-class RAR-gamma selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1344_CR39","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s13555-020-00417-4","volume":"10","author":"SM Johnson","year":"2020","unstructured":"Johnson SM, Chavda R, DuBois JC. Subject satisfaction with trifarotene 50 \u00b5g\/g cream in the treatment of facial and truncal acne vulgaris: a case series. Dermatol Ther (Heidelb). 2020;10(5):1165\u201373.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"1344_CR40","first-page":"E53","volume":"15","author":"JQ Del Rosso","year":"2022","unstructured":"Del Rosso JQ, Johnson SM, Schlesinger T, et al. A randomized, controlled trial of trifarotene plus doxycycline for severe acne vulgaris. J Clin Aesthet Dermatol. 2022;15(7):E53\u20139.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1344_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.745822","volume":"8","author":"B Dreno","year":"2021","unstructured":"Dreno B, Chavda R, Julia V, et al. Transcriptomics analysis indicates trifarotene reverses acne-related gene expression changes. Front Med (Lausanne). 2021;8: 745822.","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"1344_CR42","first-page":"734","volume":"21","author":"B Dreno","year":"2022","unstructured":"Dreno B, Kang S, Leyden J, York J. Update: mechanisms of topical retinoids in acne. J Drugs Dermatol. 2022;21(7):734\u201340.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1344_CR43","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40257-019-00454-6","volume":"20","author":"B Dreno","year":"2019","unstructured":"Dreno B, Bissonnette R, Gagne-Henley A, et al. Long-term effectiveness and safety of up to 48 weeks\u2019 treatment with topical adapalene 0.3%\/benzoyl peroxide 2.5% gel in the prevention and reduction of atrophic acne scars in moderate and severe facial acne. Am J Clin Dermatol. 2019;20(5):725\u201332.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1344_CR44","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1111\/jocd.15584","volume":"22","author":"C Bikash","year":"2023","unstructured":"Bikash C, Sarkar R. Topical management of acne scars: the uncharted terrain. J Cosmet Dermatol. 2023;22(4):1191\u20136.","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"1344_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1001\/jamafacial.2018.1404","volume":"21","author":"TP Afra","year":"2019","unstructured":"Afra TP, Razmi TM, Narang T, et al. Topical tazarotene gel, 0.1%, as a novel treatment approach for atrophic post-acne scars: a randomized active-controlled clinical trial. JAMA Facial Plast Surg. 2019;21(2):125\u201332.","journal-title":"JAMA Facial Plast Surg."},{"key":"1344_CR46","unstructured":"Galderma. LEAP and START post hoc analysis 2023. Galderma data on file."},{"issue":"3","key":"1344_CR47","first-page":"255","volume":"18","author":"J Tan","year":"2019","unstructured":"Tan J, Tanghetti E, Baldwin H, et al. The role of topical retinoids in prevention and treatment of atrophic acne scarring: Understanding the importance of early effective treatment. J Drugs Dermatol. 2019;18(3):255\u201360.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1344_CR48","first-page":"33","volume":"8","author":"MV Gozali","year":"2015","unstructured":"Gozali MV, Zhou B. Effective treatments of atrophic acne scars. J Clin Aesthet Dermatol. 2015;8(5):33\u201340.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"Suppl 1","key":"1344_CR49","first-page":"54","volume":"75","author":"R Kubba","year":"2009","unstructured":"Kubba R, Bajaj AK, Thappa DM, et al. Acne in India: Guidelines for management - IAA consensus document. Indian J Dermatol Venereol Leprol. 2009;75(Suppl 1):54.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"1344_CR50","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40257-021-00633-4","volume":"22","author":"N Elbuluk","year":"2021","unstructured":"Elbuluk N, Grimes P, Chien A, et al. The pathogenesis and management of acne-induced post-inflammatory hyperpigmentation. Am J Clin Dermatol. 2021;22(6):829\u201336.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1344_CR51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/lsm.23173","volume":"52","author":"YC Bae","year":"2020","unstructured":"Bae YC, Rettig S, Weiss E, et al. Treatment of post-inflammatory hyperpigmentation in patients with darker skin types using a low energy 1,927 nm non-ablative fractional laser: a retrospective photographic review analysis. Lasers Surg Med. 2020;52(1):7\u201312.","journal-title":"Lasers Surg Med"},{"issue":"4","key":"1344_CR52","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/ciia.2006.1.4.327","volume":"1","author":"S Mukherjee","year":"2006","unstructured":"Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327\u201348.","journal-title":"Clin Interv Aging"},{"issue":"9","key":"1344_CR53","first-page":"12","volume":"10","author":"D Connolly","year":"2017","unstructured":"Connolly D, Vu HL, Mariwalla K, Saedi N. Acne scarring-pathogenesis, evaluation, and treatment options. J Clin Aesthet Dermatol. 2017;10(9):12\u201323.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"1344_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/ijd.IJD_295_18","volume":"65","author":"S Fatima","year":"2020","unstructured":"Fatima S, Braunberger T, Mohammad TF, et al. The role of sunscreen in melasma and postinflammatory hyperpigmentation. Indian J Dermatol. 2020;65(1):5\u201310.","journal-title":"Indian J Dermatol"},{"issue":"5","key":"1344_CR55","first-page":"AB215","volume":"72","author":"R Halder","year":"2020","unstructured":"Halder R, Rodney I, Munhutu M, et al. Evaluation and effectiveness of a photoprotection composition (sunscreen) on subjects of skin of color. J Am Acad Dermatol. 2015;72(5):AB215.","journal-title":"J Am Acad Dermatol"},{"issue":"6 Suppl","key":"1344_CR56","first-page":"3","volume":"76","author":"D Berson","year":"2005","unstructured":"Berson D. Recommendation of moisturizers and cleansers: A study of unmet needs among dermatology patients. Cutis. 2005;76(6 Suppl):3\u20136.","journal-title":"Cutis"},{"issue":"4 Suppl","key":"1344_CR57","first-page":"48","volume":"68","author":"WK Jacyk","year":"2001","unstructured":"Jacyk WK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis. 2001;68(4 Suppl):48\u201354.","journal-title":"Cutis"},{"key":"1344_CR58","doi-asserted-by":"publisher","first-page":"tkad060","DOI":"10.1093\/burnst\/tkad060","volume":"12","author":"W Xu","year":"2024","unstructured":"Xu W, Sinaki DG, Tang Y, et al. Acne-induced pathological scars: pathophysiology and current treatments. Burns Trauma. 2024;12:tkad060.","journal-title":"Burns Trauma."},{"issue":"2","key":"1344_CR59","first-page":"77","volume":"105","author":"OR Ware","year":"2020","unstructured":"Ware OR, Dawson JE, Shinohara MM, Taylor SC. Racial limitations of Fitzpatrick skin type. Cutis. 2020;105(2):77\u201380.","journal-title":"Cutis"},{"key":"1344_CR60","unstructured":"Clinicaltrials.gov. NCT03915860: Participant reported outcomes with use of trifarotene 50 \u03bcg\/g cream in the treatment of moderate facial and truncal acne vulgaris. 2015. [Internet]. [cited 2024 May 12]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03915860."},{"key":"1344_CR61","unstructured":"Clinicaltrials.gov. NCT04451330: A study to compare efficacy and safety of trifarotene cream when used with an oral antibiotic for the treatment of severe acne vulgaris (DUAL). [Internet]. [cited 2024 May 12]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04451330."},{"key":"1344_CR62","unstructured":"Clinicaltrials.gov. NCT04856904: Study of trifarotene cream to assess risk of a trophic acne scar formation (START). 2024. [Internet]. [cited 2024 Feb 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04856904."},{"key":"1344_CR63","unstructured":"Clinicaltrials.gov. NCT02735421: Adapalene 0.3% - benzoyl peroxide 2.5% gel and risk of formation of atrophic acne scars (OSCAR). 2014. [Internet]. [cited 2024 May 12]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02735421."},{"issue":"1","key":"1344_CR64","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2133.1991.tb06048.x","volume":"125","author":"DW Harris","year":"1991","unstructured":"Harris DW, Buckley CC, Ostlere LS, Rustin MH. Topical retinoic acid in the treatment of fine acne scarring. Br J Dermatol. 1991;125(1):81\u20132.","journal-title":"Br J Dermatol"},{"key":"1344_CR65","unstructured":"Clinicaltrials.gov. NCT05089708: Aklief evaluation in acne-induced post-inflammatory hyperpigmentation (LEAP). 2020. [Internet]. [cited 2024 May 12]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05089708."},{"issue":"20","key":"1344_CR66","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1056\/NEJM199305203282002","volume":"328","author":"SM Bulengo-Ransby","year":"1993","unstructured":"Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328(20):1438\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"1344_CR67","first-page":"45","volume":"77","author":"P Grimes","year":"2006","unstructured":"Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77(1):45\u201350.","journal-title":"Cutis"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01344-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01344-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01344-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:35:57Z","timestamp":1741941357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01344-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1344"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01344-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Naiem Issa has acted as a speaker, consultant and\/or advisor for AbbVie, Almirall, Bristol-Myers Squibb, Castle Biosciences, Dermavant Sciences, DermTech, Galderma, Incyte, Journey, LEO Pharma, Lilly, National Eczema Association, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, SUN Pharma, UCB, Verrica Pharmaceuticals and WebMD. Prof. Andrew Alexis has received grants (funds to institution) from LEO Pharma, Amgen, Galderma, Arcutis, Dermavant, AbbVie and Castle; participated on advisory boards or as a consultant for LEO Pharma, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Ortho, L\u2019Or\u00e9al, Bristol-Myers Squibb, Bausch Health, UCB Pharma, Arcutis, Janssen Pharmaceuticals, Allergan, Almirall, AbbVie, Amgen, VisualDx, Eli Lilly, Swiss American, Cutera, Cara Therapeutics, EPI Health, Incyte Corporation, Castle, Apogee, Alphyn, Canfield, Avita Medical and Genentech; acted as a speaker for Regeneron, Sanofi, Bristol-Myers Squibb, L\u2019Or\u00e9al, Janssen Pharmaceuticals and Johnson & Johnson; received royalties from Springer, Wiley-Blackwell and Wolters Kluwer Health; received equipment from Aerolase. Dr. Hilary Baldwin has acted as an investigator, consultant and\/or speaker for Almirall, Bausch Health, Cassiopeia, EPI Health, Galderma, La Roche-Posay, L\u2019Or\u00e9al, Mayne Pharma, Sol\u2013Gel, Sun Pharma and Vyne. Dr. Iltefat Hamzavi has acted as a consultant and investigator AbbVie, Pfizer, Incyte, UCB, Boehringer Ingelheim, Sonoma, Union therapeutics, Novartis, Jansen, ITN, Avita, Galderma, Vimela, Almirall, Sonoma, Boehringer Ingelheim and Merck. Dr. Adelaide Hebert has received research grants paid to UTHealth McGovern Medical School from Galderma, Ortho Dermatologics, Pfizer, Arcutis, Dermavant, Amgen, Lilly, Leo Pharma; honoraria for consultation\/speaker\/advisor: Pfizer, Arcutis, Dermavant, Leo Pharma, Incyte, Almirall, Lilly, Beiersdorf and LaRoche-Posay. Dr. Pearl Kwong has acted as investigator, or consultant or speaker for Almirall, Bausch Health\/Ortho, Galderma, Cerave, Apogee, AbbVie, Arcutis, Dermavant, Incyte, Sanofi\/Regeneron, Pfizer, Eli Lilly, EPI Health UCB, Amgen, Bristol-Myers Squibb, Leo, Sun Pharma, Verrica Pharmaceuticals, Novan, Journey Pharmaceuticals and Novartis. Dr. Edward Lain has served as an investigator, speaker, advisor and\/or consultant for AbbVie, Almirall, Amgen, Arcutis, Bausch, Beiersdorf, Bristol-Myers Squibb, Cassiopeia, Cellceutix, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Kenvue, LEO, L\u2019Oreal, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi, Sun Pharma, Takeda, UCB Pharma and Vyne. Dr. Angela Moore has received honoraria or research funds from Almirall, Galderma, Mayne, Ortho Dermatologics, Parexel and Vyne. Dr. Omar Noor is a speaker, consultant and\/or advisor for AbbVie, Almirall, Amgen Inc, Arcutis, Bristol-Myers Squibb, Castle Biosciences, Dermavant Sciences, DermTech, Galderma, Incyte Corporation, Journey Medical, LEO Pharma, Lilly, Novartis Pharmaceuticals Corporation, Ortho Dermatologics, Pfizer, Procter & Gamble Ventures, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Sun Pharmaceutical Industries Ltd and UCB. Dr. Todd Schlesinger serves as a consultant, investigator, speaker and\/or advisor for AbbVie, Almirall, Allergan (An AbbVie company), ASLAN Pharma, Arcutis, Biofrontera, Beiersdorf, Benev, Bristol-Myers Squibb, Castle Biosciences, Galderma, Eli Lilly, ExoCoBio, Incyte, Janssen, LEO, L\u2019Oreal, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, UCB Pharma and Verrica Pharmaceuticals. Dr. Jonathan Weiss serves as an advisory board member for Bristol-Myers Squibb, Dermavant Sciences, Foamix, Galderma Laboratories, L.P., Incyte Corporation, Novartis and UCB receiving honoraria; as a consultant for Arcutis, Inc., Biofrontera, Cutera, Inc., Leo Pharma Inc, Ortho Dermatologics and UCB receiving fees or honoraria; as an investigator for AbbVie, Bausch Health, Biofrontera, Bristol-Myers Squibb, Cutera, Inc., Dermavant Sciences, Foamix, Galderma, L.P., LEO Pharma, Mindera, Moberg Pharma North, America LLC, Novartis, Palvella Therapeutics and Verrica Pharmaceuticals Inc receiving grants and research funding; as a speaker for AbbVie, Arcutis, Inc., Galderma, L.P., Ortho Dermatologics, Regeneron and Sanofi Genzyme receiving honoraria. Dr. Heather Woolery-Lloyd has served as a research\/investigator for AbbVie, Allergan, Eirion Therapeutics, Galderma, Pfizer and Arcutis. An advisor\/consultant for Ortho Dermatologics, AbbVie, Incyte, Johnson & Johnson Consumer, Inc., L\u2019Or\u00e9al, Arcutis, Beiersdorf, Unilever, Procter & Gamble, SC Johnson, Kenvue and Galderma. Acted on the speakers' bureau for Incyte, L\u2019Or\u00e9al, Ortho Dermatologics, Pfizer and Galderma. Dr. JP York is an employee of Galderma. Dr. Katherine (Kate) Zibilich Holcomb has served as an investigator, speaker, advisor and\/or consultant for AbbVie, Almirall, Bristol Myers Squibb, Galderma, Incyte and Sun Pharma. Prof. Leon Kircik has received research grants from AbbVie, Allergan, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Breckenridge Pharma, Bristol-Myers Squibb, Celgene, Cellceutix, Centocor, Combinatrix, Connetics, Coria, Dermavant, Dermira, Dow Pharma, Dr Reddy\u2019s Laboratories, Eli Lilly, Galderma, Genentech, GlaxoSmithKline, Idera, Johnson & Johnson, LEO Pharma, Maruho, Merck, Medicis, Novartis AG, Pfizer, PharmaDerm, Promius, Stiefel, Sun Pharma, UCB Pharma, Valeant and XenoPort; has received honoraria from AbbVie, Allergan, Almirall, Amgen, Arcutis, Biogen Idec, Bristol-Myers Squibb, Celgene, Cipher, Connetics, Dermavant, Dermira, Dr Reddy\u2019s Laboratories, Eli Lilly, Galderma, Genentech, GlaxoSmithKline, Johnson & Johnson, LEO Pharma, Merck, Novartis AG, PharmaDerm, Promius, Serono (Merck Serono International SA), Stiefel, Sun Pharma, Taro, UCB Pharma and Valeant. Dr. Rajeev Chavda is an employee of Galderma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Information presented in this article is based on previously conducted studies and does not contain any data from new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}